Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Liraglutide 3 mg for Knee Osteoarthritis (LOSEIT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02905864
Recruitment Status : Completed
First Posted : September 19, 2016
Last Update Posted : March 25, 2019
Sponsor:
Collaborators:
Novo Nordisk A/S
Cambridge Weight Plan Limited
Information provided by (Responsible Party):
Henrik Gudbergsen, Parker Research Institute

Brief Summary:

A randomised, double blind, placebo-controlled, parallel group, and single-centre trial investigating the effect of liraglutide on body weight and pain in overweight or obese patients with knee osteoarthritis.

Patients will be subjected to a run-in diet intervention phase (week -8 to 0) including a low-calorie diet and dietetic counselling. At week 0 patients will be randomised to receive either liraglutide 3 mg or liraglutide 3 mg placebo as an add-on to dietetic guidance on re-introducing regular foods and a focus on continued motivation to engage in a healthy lifestyle.


Condition or disease Intervention/treatment Phase
Osteoarthritis Obesity Drug: Liraglutide 3 mg (Saxenda) Drug: Liraglutide 3 mg placebo Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 150 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Effect of Liraglutide on Body Weight and Pain in Overweight or Obese Patients With Knee Osteoarthritis: A Randomised, Double Blind, Placebo-controlled, Parallel Group, Single-centre Trial
Study Start Date : November 2016
Actual Primary Completion Date : February 2019
Actual Study Completion Date : March 2019

Resource links provided by the National Library of Medicine

Drug Information available for: Liraglutide

Arm Intervention/treatment
Experimental: Liraglutide 3 mg

Arm description: Subjects will be up titrated to liraglutide 3 mg QD and stay on that dose for the remainder of the 52-week drug intervention period.

Drug: Liraglutide 3 mg QD administered in a 6 mg/mL, 3 mL pen for subcutaneous injection.

Dose escalation scheme: Initial dosage of 0.6 mg per day, escalated bi-weekly by 0.6 mg to 3 mg per day over a total of 8 weeks.

Drug: Liraglutide 3 mg (Saxenda)
Placebo Comparator: Liraglutide 3 mg placebo

Arm description: Subjects will be up titrated to liraglutide 3 mg placebo QD and stay on that dose for the remainder of the 52-week drug intervention period.

Drug: Liraglutide 3 mg placebo QD administered in a 6 mg/mL drug equivalent volumes, 3 mL pen for subcutaneous injection.

Dose escalation scheme: Initial dosage of a 0.6 mg drug equivalent volume per day, escalated bi-weekly by an 0.6 mg drug equivalent volume per day to a 3 mg drug equivalent volume per day over a total of 8 weeks.

Drug: Liraglutide 3 mg placebo



Primary Outcome Measures :
  1. Change in body weight [ Time Frame: Week 0 to 52 ]
    One of two co-primary outcomes

  2. KOOS pain subscale [ Time Frame: Week 0 to 52 ]
    Two of two co-primary outcomes. The Knee injury and Osteoarthritis Outcome Score (KOOS); the pain subscale (9 items)


Secondary Outcome Measures :
  1. KOOS symptom subscale [ Time Frame: Week 0 to 52 ]
    Knee injury and Osteoarthritis Outcome Score (KOOS); the symptoms subscale (7 items)

  2. KOOS ADL subscale [ Time Frame: Week 0 to 52 ]
    Knee injury and Osteoarthritis Outcome Score (KOOS); the Activities of Daily Living (ADL) subscale (17 items)

  3. KOOS sport and recreation subscale [ Time Frame: Week 0 to 52 ]
    Knee injury and Osteoarthritis Outcome Score (KOOS); the sport and recreation subscale (5 items)

  4. KOOS health related QoL subscale [ Time Frame: Week 0 to 52 ]
    Knee injury and Osteoarthritis Outcome Score (KOOS); the health related quality of life (QoL) subscale (4 items)

  5. Change in total score in the ICOAP questionnaire [ Time Frame: Week 0 to 52 ]
    The Intermittent and Constant Osteoarthritis Pain questionnaire (ICOAP); 11 items

  6. Change in the constant pain subscale in the ICOAP questionnaire [ Time Frame: Week 0 to 52 ]
    The Intermittent and Constant Osteoarthritis Pain questionnaire (ICOAP); 5 items

  7. Change in the intermittent pain subscale in the ICOAP questionnaire [ Time Frame: Week 0 to 52 ]
    The Intermittent and Constant Osteoarthritis Pain questionnaire (ICOAP); 6 items

  8. Change in the Western Ontario and McMaster Universities Arthritis Index (WOMAC) pain subscale [ Time Frame: Week 0 to 52 ]
    The Western Ontario and McMaster Universities Arthritis Index (WOMAC) pain subscale; 5 items

  9. Change in the Western Ontario and McMaster Universities Arthritis Index (WOMAC) stiffness subscale [ Time Frame: Week 0 to 52 ]
    The Western Ontario and McMaster Universities Arthritis Index (WOMAC) stiffness subscale; 2 items

  10. Change in the Western Ontario and McMaster Universities Arthritis Index (WOMAC) physical function subscale [ Time Frame: Week 0 to 52 ]
    The Western Ontario and McMaster Universities Arthritis Index (WOMAC) physical function subscale; 17 items

  11. Proportion of participants with ≥5% weight loss [ Time Frame: Week 0 to 52 ]
    The proportion of patients with or with more than a 5% weight loss 52 weeks after randomization

  12. Proportion of participants with ≥10% weight loss [ Time Frame: Week 0 to 52 ]
    The proportion of patients with or with more than a 10% weight loss 52 weeks after randomization

  13. Change in BMI [ Time Frame: Week 0 to 52 ]
    Change in body mass index 52 weeks after randomization

  14. Change in waist circumference [ Time Frame: Week 0 to 52 ]
    Change in waist circumference 52 weeks after randomization

  15. Change in waist/hip circumference ratio [ Time Frame: Week 0 to 52 ]
    Change in the ratio waist circumference/hip circumference 52 weeks after randomization



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 74 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Informed consent obtained
  • Clinical diagnosis of knee OA (American College of Rheumatology (ACR) criteria) confirmed by radiology but restricted to definite radiographic OA at early to moderate-stages (Kellgren-Lawrence grades 1, 2, or 3)
  • Age ≥ 18 years and < 75 years
  • Body mass index (BMI) ≥ 27 kg/m2
  • Stable body weight during the previous 3 months (< 5 kg self-reported weight change)
  • Motivated for weight loss

Exclusion Criteria:

  • On-going participation, or participation within the last 3 months, in an organised weight loss programme (or within the last 3 months)
  • Current or history of treatment with medications that may cause significant weight gain for at least 3 months before this trial
  • Current use or use within three months before this trial of GLP-1 receptor agonist, pramlintide, sibutramine, orlistat, zonisamide, topiramate, or phentermine
  • Type 1 diabetes
  • Type 2 diabetes treated with glucose-lowering drugs other than metformin
  • Alloplasty in target knee joint (see section 6.3)
  • End stage disease in target knee joint (Kellgren-Lawrence grade 4)
  • Immuno-inflammatory disease
  • Chronic wide-spread pain
  • Pregnancy or insufficient anti-conception therapy for female fertile patients
  • Breast-feeding
  • Estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73 m2
  • Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 3 x above upper normal range (UNR)
  • Surgery scheduled for the trial duration period, except for minor surgical procedures
  • Surgical procedures such as arthroscopy or injections into a knee within 3 months prior to enrolment
  • Previous surgical treatment for obesity (excluding liposuction >1 year before trial entry)
  • Thyroid stimulating hormone (TSH) outside of the range of 0.4-6.0 mIU/L
  • Obesity secondary to endocrinologic or eating disorders or to treatment with medicinal products that may cause weight gain
  • Family or personal history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2
  • Inflammatory bowel disease
  • Congestive heart failure, New York Heart Association (NYHA) class III-IV
  • Diabetic gastroparesis
  • History of or current diagnosis of pancreatitis (acute and/or chronic) or pancreatic cancer
  • History of cancer with the exception of in-situ malignancies of the skin or cervix uteri
  • History of major depressive disorder, a PHQ-9 (Patient Health Questionnaire-9) score of more than 15, or a history of other severe psychiatric disorders or diagnosis of an eating disorder
  • Subjects with a lifetime history of a suicide attempt or history of any suicidal behaviour within the past month before entry into the trial
  • Inability to speak Danish fluently
  • A mental state impeding compliance with the program
  • Use of opioids or similar strong analgesics
  • Allergic reactions to the active ingredients of Saxenda, such as hypotension, palpitations, dyspnoea and oedema

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02905864


Locations
Layout table for location information
Denmark
Department of Rheumatology
Frederiksberg, Capital Region, Denmark, 2000
Sponsors and Collaborators
Henrik Gudbergsen
Novo Nordisk A/S
Cambridge Weight Plan Limited
Investigators
Layout table for investigator information
Principal Investigator: Henrik R Gudbergsen, MD, PhD The Parker Institute

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Henrik Gudbergsen, MD, PhD, Parker Research Institute
ClinicalTrials.gov Identifier: NCT02905864     History of Changes
Other Study ID Numbers: 137.00
First Posted: September 19, 2016    Key Record Dates
Last Update Posted: March 25, 2019
Last Verified: March 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by Henrik Gudbergsen, Parker Research Institute:
Liraglutide
Liraglutide 3 mg
Osteoarthritis
Obesity
Additional relevant MeSH terms:
Layout table for MeSH terms
Osteoarthritis
Osteoarthritis, Knee
Arthritis
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Liraglutide
Hypoglycemic Agents
Physiological Effects of Drugs
Incretins
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists